Rentschler Biopharma is more than just a CDMO, we are a valuable strategic partner to grow with. We shift boundaries - Together with our partners.


Federico Pollano

Senior Vice President Global Business Development

With over 30 years of broad-based experience in successfully leading business development activities, strategy and growing CDMO businesses – I bring your ideas to life!

Grace Kim

Vice President Business Development North America

A strong belief in strategic partnerships to maximize growth underlies my experience of over 20 years in leadership roles across the biopharmaceutical value chain.

Lucia Kirchgeorg

Director Business Development

I strongly believe that a mutual partnership approach is key to finding premium best-fit solutions to bring your outstanding biopharmaceuticals to patients.

Marine Maestracci

Director Business Development

France, Spain, Italy, BeNeLux, Switzerland

Understand, exchange and collaborate. Together, we can tailor and deliver the best approach to bring your innovative biopharmaceuticals to patients.

Dr. Daniel Mattle

Senior Director Business Development 

Switzerland, Austria, Eastern Europe, Scandinavia, Middle East, Japan

I am dedicated to supporting you in manufacturing therapeutic biologics to tackle the unmet medical needs of today.

Dr. Patrick Meyer

Senior Director Business Development

DACH, BeNeLux, UK, Ireland, Australia/New Zealand, South Africa, South America

I am committed and prepared to go the distance in helping you achieve your goals in bringing treatments to patients more easily and faster.

Dr. Konstantin Kazarian

Senior Director Business Development

North America

With 20 years of experience my mission is to provide top-quality, reliable CDMO services assuring clients that their critically important biologics will reach patients in need.

Yukari Tokuyama, PhD

Director Business Development

North America

By building long-term partnerships, we provide timely and tailormade solutions to bring your biopharmaceuticals and advanced therapeutics, such as cell and gene therapie, to patients in need.